Journal
How Much Does Semaglutide Cost in 2026? Every Channel, One Answer
Released: Last reviewed:
The short answer
Semaglutide's 2026 board, floor to ceiling. Insured: $25 commercial copays where Wegovy coverage exists (the SELECT cardiovascular indication opening doors weight exclusions close), Ozempic riding diabetes formularies with a T2D diagnosis. Compounded cash: the market's lowest GLP-1 figures — $129–$139 month-to-month on the August record (bmiMD $129, HealthRX's $133 three-month; NexLife's $139 until November 6, 2026), $99 committed at two programs, and on October 15, 2026 Eden listed $99 a month flat with no membership. Brand oral: NovoCare's Wegovy tablets from $149 (1.5 mg; $199 at 4 mg and $299 at 9 and 25 mg on October 15, 2026) — the approved product camped close to the compounded floor at its starting dose, the class's most interesting squeeze. Brand pens: $349 standard ($399 at the 7.2 mg tier) with a $199 introduction on the first two starter fills through year-end. Routing: coverage first; then the oral-versus-injectable-versus-compounded triangle the semaglutide flagship maps.
The annual math, and the squeeze
Twelve months, each lane: insured $300; compounded floor $1,188–$1,668 ($99 committed to $139 monthly); oral brand ~$1,788–$3,588 a year depending on dose ($149 at 1.5 mg to $299 at 9 and 25 mg); pens ~$4,088 year one (two intro months at $199, ten at $349) or $4,188 steady-state. The squeeze deserves its own sentence: at $149 for the 1.5 mg tablet versus $129 month-to-month compounded on the August record, the FDA-approved tablet cost twenty dollars a month more than the lowest compounded injection then tracked (fifty more against Eden's $99 flat price on October 15, and the higher tablet doses cost $199–$299) — no verification homework, no compounding-lane questions, manufactured product — which is the strongest brand-value argument in either molecule and the reason our semaglutide rankings route needle-averse and simplicity-first buyers there before any compounded row. What keeps compounded's half of the market: injection preference at the floor price, dose-flat economics, and the $99 committed tier the tablet can't reach. The standing rules ride along: all-ins only (membership fees inside), maintenance prices only (no "from" figures), named pharmacies only — the teaser index polices the rest.
Questions people ask
What's the cheapest semaglutide option in 2026?
On October 15, 2026, Eden listed compounded semaglutide at $99 a month flat with no membership. On the August record, committed compounded plans at $99/month (bmiMD, HealthRX — twelve-month terms, billing shapes vary) came next, then $129–$139 month-to-month. The wildcard: FDA-approved oral Wegovy from $149 at the 1.5 mg dose — a manufactured, approved product close to the compounded floor. Insurance beats everything where it applies.
How much is Wegovy without insurance?
Direct from NovoCare: $349/month pens ($399 for the 7.2 mg tier), with a $199 introductory price on the first two starter-dose fills through December 31, 2026 — or oral tablets from $149. Resellers charge more for the same product ($448+ all-in at Hims); the manufacturer's counter is the cash benchmark.
Is compounded semaglutide worth it versus the $149 oral tablet?
The honest close call of the class: $129–$139 compounded injectable versus the $149 approved 1.5 mg tablet is a $10–$20/month gap (higher tablet doses cost $199–$299). The tablet buys FDA approval and zero verification homework at the cost of the strict empty-stomach ritual; compounded keeps the injection route and the $99 committed floor. Preference decides; both beat the $200+ tier.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.